Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Peter Wyngaard"'
Autor:
Daniel H. Hovelson, Andrew S. McDaniel, Andi K. Cani, Bryan Johnson, Kate Rhodes, Paul D. Williams, Santhoshi Bandla, Geoffrey Bien, Paul Choppa, Fiona Hyland, Rajesh Gottimukkala, Guoying Liu, Manimozhi Manivannan, Jeoffrey Schageman, Efren Ballesteros-Villagrana, Catherine S. Grasso, Michael J. Quist, Venkata Yadati, Anmol Amin, Javed Siddiqui, Bryan L. Betz, Karen E. Knudsen, Kathleen A. Cooney, Felix Y. Feng, Michael H. Roh, Peter S. Nelson, Chia-Jen Liu, David G. Beer, Peter Wyngaard, Arul M. Chinnaiyan, Seth Sadis, Daniel R. Rhodes, Scott A. Tomlins
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 17, Iss 4, Pp 385-399 (2015)
Next-generation sequencing (NGS) has enabled genome-wide personalized oncology efforts at centers and companies with the specialty expertise and infrastructure required to identify and prioritize actionable variants. Such approaches are not scalable,
Externí odkaz:
https://doaj.org/article/e35c27ad1bb744a8a1d6afe2cf1f770b
Autor:
Arul M. Chinnaiyan, Dan R. Robinson, Daniel R. Rhodes, Kenneth J. Pienta, Moshe Talpaz, Mark M. Zalupski, Felix Y. Feng, Maha H. Hussain, Sameek Roychowdhury, Seth Sadis, Peter Wyngaard, Scott A. Tomlins, Javed Siddiqui, Lakshmi P. Kunju, Ann-Joy Cheng, Su-Fang Lin, Rui Wang, Pankaj Vats, Robert J. Lonigro, Xuhong Cao, Bushra Ateeq, Nickolay Khazanov, Shanker Kalyana-Sundaram, Fengyun Su, Yi-Mi Wu
Supplementary Tables - PDF file 753K, Supplementary Tables S1-S15 include transcriptome and exome sequencing results for the FGFR fusion positive index cases, and summaries of sequencing cohorts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::302c6117c2beed495c802f160a6d0cba
https://doi.org/10.1158/2159-8290.22530761.v1
https://doi.org/10.1158/2159-8290.22530761.v1
Autor:
Arul M. Chinnaiyan, Dan R. Robinson, Daniel R. Rhodes, Kenneth J. Pienta, Moshe Talpaz, Mark M. Zalupski, Felix Y. Feng, Maha H. Hussain, Sameek Roychowdhury, Seth Sadis, Peter Wyngaard, Scott A. Tomlins, Javed Siddiqui, Lakshmi P. Kunju, Ann-Joy Cheng, Su-Fang Lin, Rui Wang, Pankaj Vats, Robert J. Lonigro, Xuhong Cao, Bushra Ateeq, Nickolay Khazanov, Shanker Kalyana-Sundaram, Fengyun Su, Yi-Mi Wu
Supplementary Figures - PDF file 639K, Supplementary Figures S1-S9 show the phenotypic effects and signaling pathways of FGFR fusions in vitro and in vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f47902b379563a198cf391c4c005834
https://doi.org/10.1158/2159-8290.22530764.v1
https://doi.org/10.1158/2159-8290.22530764.v1
Autor:
Moshe Talpaz, Mark M. Zalupski, Seth Sadis, Robert J. Lonigro, Dan R. Robinson, Ann Joy Cheng, Arul M. Chinnaiyan, Daniel R. Rhodes, Pankaj Vats, Rui Wang, Kenneth J. Pienta, Sameek Roychowdhury, Nickolay A. Khazanov, Shanker Kalyana-Sundaram, Peter Wyngaard, Javed Siddiqui, Maha Hussain, Felix Y. Feng, Xuhong Cao, Bushra Ateeq, Lakshmi P. Kunju, Su-Fang Lin, Scott A. Tomlins, Yi-Mi Wu, Fengyun Su
Publikováno v:
Cancer discovery. 3(6)
Through a prospective clinical sequencing program for advanced cancers, four index cases were identified which harbor gene rearrangements of FGFR2, including patients with cholangiocarcinoma, breast cancer, and prostate cancer. After extending our as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb26398229aa85678136b00ce37c2f03
https://pubmed.ncbi.nlm.nih.gov/23558953
https://pubmed.ncbi.nlm.nih.gov/23558953
Autor:
Daniel R. Rhodes, Nickolay A. Khazanov, Paul D. Williams, Emma Bowden, Sean Eddy, Mark Tomilo, Seth Sadis, Peter Wyngaard
Publikováno v:
European Journal of Cancer. 48:152-153
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3250861433d1120fc23644d265ed3a85
https://doi.org/10.1016/s0959-8049(12)72290-6
https://doi.org/10.1016/s0959-8049(12)72290-6
Autor:
Dinesh Cyanam, Peter Wyngaard, Paul D. Williams, Mary Ellen Urick, Sean Eddy, Armand Bankhead, Daniel Rhodes, Supra R. Gajjala, Nickolay A. Khazanov, Mark Tomilo, Emma Bowden
Publikováno v:
Molecular Cancer Therapeutics. 12:C256-C256
Patients with chromosomal rearrangements resulting in fusion proteins are amongst the most responsive to targeted therapy. For example, targeting of the BCR-ABL fusion in chronic myelogenous leukemia (CML) with imatinib and the EML4-ALK fusion in non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea8d58bbbfbbd879ea0e86f8a528d227
https://doi.org/10.1158/1535-7163.targ-13-c256
https://doi.org/10.1158/1535-7163.targ-13-c256
Autor:
Sean Eddy, Daniel R. Rhodes, Armand Bankhead, Peter Wyngaard, Dinesh Cyanam, Nikolay Khazanov, Paul J. Williams, Emma Bowden
Publikováno v:
Journal of Clinical Oncology. 31:11017-11017
11017 Background: Cancer driver events occur as a result of chromosomal rearrangements. There are several examples where targeted inhibition of the resulting fusion produces dramatic clinical response. For example, the EML4-ALK fusion in non-small ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca82ebcc39495bcd67ae76e316807416
https://doi.org/10.1200/jco.2013.31.15_suppl.11017
https://doi.org/10.1200/jco.2013.31.15_suppl.11017
Autor:
Santhoshi Bandla, Sean Eddy, Supra R. Gajjala, Daniel R. Rhodes, Peter Wyngaard, Seth Sadis, Paul D. Williams, Emma T. Bowden, Mark Tomilo, Nickolay A. Khazanov
Publikováno v:
Cancer Research. 73:2897-2897
The MAPK and PI3K pathways are frequently altered in human cancer and are targeted by dozens of agents in clinical trials. The successful application of these therapies, alone or in combination, may depend on the activation status of both pathways. N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c605edee540c04d4e8a86c8b39e9236b
https://doi.org/10.1158/1538-7445.am2013-2897
https://doi.org/10.1158/1538-7445.am2013-2897
Autor:
Emma Bowden, Daniel R. Rhodes, Seth Sadis, Paul D. Williams, Nickolay A. Khazanov, Peter Wyngaard, Scott A. Tomlins
Publikováno v:
European Journal of Cancer. 48:134
Background: Next generation sequence analysis of cancer exomes provides a comprehensive assessment of somatic mutations; however discerning often rare driver mutations from abundant passenger mutations remains a challenge. Unlike other approaches tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a9b6727e487e91e1cf3de02f1cecfcc
https://doi.org/10.1016/s0959-8049(12)72228-1
https://doi.org/10.1016/s0959-8049(12)72228-1
Autor:
Sean Eddy, Lien Vo, Joseph Monforte, Mark Tomilo, Peter Wyngaard, Yipeng Wang, Paul J. Williams, Hyun-Chul Kim, Daniel R. Rhodes, Byung-In Lee, Seth Sadis, Kahuku Oades
Publikováno v:
Journal of Clinical Oncology. 30:e14164-e14164
e14164 Background: While KRAS mutation predicts resistance to anti-EGFR therapy in colorectal cancer, not all KRAS wild-type patients benefit from such therapy, suggesting that complementary biomarkers capable of identifying additional non-responsive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59accf6708550211a5b30ee77380f299
https://doi.org/10.1200/jco.2012.30.15_suppl.e14164
https://doi.org/10.1200/jco.2012.30.15_suppl.e14164